A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.
about
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Fluoroquinolones for treating tuberculosisMycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulenceDuration of therapy for tuberculosis in patients infected with Human Immunodeficiency VirusAdherence to tuberculosis therapy among patients receiving home-based directly observed treatment: evidence from the United Republic of Tanzania.Initiation of antiretroviral therapy.Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study.Assessment of patient preference in allocation and observation of anti-tuberculosis medication in three districts in TanzaniaReplication dynamics of Mycobacterium tuberculosis in chronically infected miceTreatment Options for HIV-Associated Tuberculosis.Culture conversion rate at 2 months of treatment according to diagnostic methods among patients with culture-positive pulmonary tuberculosis.Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru.Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana.Antitubercular Nanocarrier Combination Therapy: Formulation Strategies and in Vitro Efficacy for Rifampicin and SQ641.Treatment outcomes of patients with HIV and tuberculosis.A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adultsClose contact interferon-gamma response to the new PstS1(285-374):CPF10: a preliminary 1-year follow-up study.Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.Coinfections associated with human immunodeficiency virus infection: workshop 1A.Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB.Management of co-infection with HIV and TB.Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.HIV-TB Coinfection among 57 Million Pregnant Women, Obstetric Complications, Alcohol Use, Drug Abuse, and Depression.
P2860
Q24202081-BADF2836-4567-4CF6-8476-05CC34CA74D6Q24242773-DFC08A21-4034-4A98-8E34-AD0D0D357612Q24544255-20D55009-29DC-4B09-9736-5D7F9CA9764DQ26471837-2A3F4572-2706-4163-ACF7-416E9AD7C405Q28484444-8D7CC30F-F21E-4BD3-8A79-E3E7BE3070F8Q30209635-C26A0E1A-7E7F-455F-8351-7232A1CFF974Q30397124-BD9B4425-512D-466A-AA83-0D2C232CCCEEQ30397192-D1AF0978-144E-46BC-AC92-8A3156086D06Q33557117-9D1AEB4E-6D4F-4AC0-A28A-22E5D0603D4AQ33813097-D5E984B0-B9C6-432F-91C5-5D59F27F1CE1Q34020372-8A61D86B-EA97-451D-8F27-1E379799B6F9Q34030008-A9D86D02-5BC4-47B5-8445-B350B14051FCQ34512904-AF6F2A0D-3AE7-4E2E-BE4E-09C28A49B0A2Q35043048-5EA6C330-C6C5-4AE1-8ECF-E7339050133BQ35173497-CED93B7F-1A9A-4CD7-B143-DD9C0D33951EQ35579500-510FBAD7-4FFE-4FDD-BCB2-0E513C12D119Q35855154-AE61E192-734A-4E0E-9A0F-5578C0463425Q35889153-7B5C4548-0CAC-4BD9-96E2-8AC1A640AEE0Q36258046-9980FF67-96BD-40C7-A405-C4281D69F9D5Q37369594-E08D4619-BD61-4244-B016-F9589C8F27E7Q37461125-4A08EE55-BADD-42A2-A32E-2EBB2E8D4085Q37858317-269E3339-E05C-46A0-ACC0-B5AE60FF3E3BQ38684466-EA23CF34-3A83-45BC-A300-9C4F205825ECQ38839490-05707B7F-9078-4DA7-9E2E-14250B1643EDQ39713565-9C2F9BB4-C4D2-424D-ACC8-8BE627956749Q40226194-DF757CF7-A81F-4072-94D8-AF3CCC1B1DB8Q42776942-D8B4283C-52F5-4926-A6AA-C43FA0A91708Q43228809-8FE09336-16BA-455B-B879-376FB5924434Q44386599-75D5C2C7-FEA4-430E-BACC-78CF1920EA2BQ45734056-02DCE651-E772-4561-84B5-6E4A0D82E36EQ46169240-764B3903-2B96-4EBB-9DF4-AE2815545767Q47102399-19BCFA36-38AB-499A-86E9-E3CC41E0734BQ54261737-2E1E9991-6494-4E66-BEDC-4DDC0F56CBF7
P2860
A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A review of efficacy studies o ...... differences in study outcomes.
@ast
A review of efficacy studies o ...... differences in study outcomes.
@en
A review of efficacy studies o ...... differences in study outcomes.
@nl
type
label
A review of efficacy studies o ...... differences in study outcomes.
@ast
A review of efficacy studies o ...... differences in study outcomes.
@en
A review of efficacy studies o ...... differences in study outcomes.
@nl
prefLabel
A review of efficacy studies o ...... differences in study outcomes.
@ast
A review of efficacy studies o ...... differences in study outcomes.
@en
A review of efficacy studies o ...... differences in study outcomes.
@nl
P2093
P2860
P356
P1476
A review of efficacy studies o ...... differences in study outcomes.
@en
P2093
P2860
P304
P356
10.1086/318706
P407
P577
2001-02-09T00:00:00Z